Impact of C-arm CT in Decreased Renal Function Undergoing TACE for Tx of Hepato-Cellular Carcinoma

N/ATerminatedNCT01326390

Stanford University13 enrolled

Overview

Impact on contrast dose or total volume of contrast required to effectively treat the targeted tumor.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Kidney (Renal Cell) Cancer

Interventions

dTA/dBA C-arm fluoroscopy system with Dyna CTDEVICE

C-arm CT of the liver; state-of-the-art flat panel detector on a ceiling or floor mounted C-arm gantry

DSA arteriogram- hepatic arteriesPROCEDURE

Standard of care

CO2 aortogramPROCEDURE

Standard of care

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients must be affected by HCC 2. Patients must have diminished renal function (GFR\<60 ml/min/1.73m\^2) 3. Patients must be 18 years old or older 4. Patients must have received an abdominal CT, PET/CT scan or MRI, completed prior to the TACE procedure. 5. Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: 1. Subjects under the age of 18 2. Patients currently on dialysis 3. Pregnant women

Locations (1)

Stanford University School of Medicine

Stanford, California, United States

Outcomes

Primary Outcomes

Proportion of patients that develop renal failure (defined as a decline of renal function, as measured by glomerular filtration rate, of 25% or more from pre-procedural)

Time frame: 3 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.